

Compound		Compound properties										Max DDI Observed					Route of Admin		ΔAUC(%)	
CAS number	NAME	fe			F		Renal	Non-renal	Enzyme(s)		Transporter(s)	Route of Admin	Δ%AUC	Δ%CL/F	inhibitor	Ref DDI		mild (CP score 5 or 6)	moderate (CP score 7 to 9)	
		iv	other than iv (po if not indicated)	ref (PMID if not specified)	po vs. iv (if not indicated)	ref (PMID if not specified)				ref (PMID if not specified)										
128196-01-0	(S)-citalopram	0.08				PL	NO	YES	CYP2C19, CYP3A4	PL	P-gp (citalopram)	po	91.4	-57.1	omeprazole	20642546	po	51.7	69.1	
119141-88-7	(S)-omeprazole		<0.01		0.50 - 0.68	11214773	NO	YES	CYP2C19, CYP3A4	PL	P-gp (omeprazole)	po	127.2		clarithromycin and amoxicillin	16550734	po	42.2	76.6	
154229-19-3	abiraterone		0.05 (total radioactivity)	PL			NA	YES	CYP3A4, SULT2A1	PL					No DDI Study with AUC or CL Change in DIB		po	10.6	386.6	
616-91-1	acetylcysteine	0.29		3803419	0.06-0.10	3803419	NO	YES	Not specified	PL					No DDI Study with AUC or CL Change in DIB		iv		62.2	
727649-81-2	acidinium	0.01		PL	0.06	PL	NO	YES	Hydrolysis	PL					No DDI Study with AUC or CL Change in DIB					
59277-89-3	acyclovir	0.76		6355048	0.1 - 0.2	PL	YES	NO	Not specified	PL	MATE1, MATE2	iv	40	-29.9	probenecid	7103460				
71195-58-9	alfentanil	0.01		PL	0.42	15536460	NO	YES	CYP3A	DIBD		po	35.50	-97.6	indinavir and ritonavir	19225389	iv	206.2	285.8	
81403-80-7	alfuzosin		0.041 - 0.076	NDA 021287	0.49	PL	NO	YES	CYP3A	PL	P-gp	po	197		ketoconazole	NDA 021287	po			
173334-57-1	aliskiren		0.0004	NDA 021985	0.025	PL	NO	YES	CYP3A4	PL		po	533.1		itraconazole	20400651	po	9.3	31.5	
850649-61-5	alogliptin		0.60 - 0.71	PL	1.0	PL	YES	YES	CYP2D6, CYP3A4	PL		po	15.4		ketoconazole	NDA 022271	po		-17.8	
156053-89-3	alvimopan		0.021	NDA 021775	0.06	PL	NO	YES	Hydrolysis	PL	P-gp	po	-12.2		cefprozil	19797535	po	112.3	82.2	
177036-94-1	ambrisentan						NO	YES	CYP 3A4, CYP 2C19, UGT	PL	P-gp	po	121.3		cyclosporine	20811346				
161814-49-9	amprenavir		0.01	PL			NA	YES	CYP3A4	PL	P-gp	po	302.3	-74.9	delavirdine	12496743	po	22.3	70.1	
166663-25-8	anidulafungin	<0.01		PL		7075648	NO	YES	Not specified	PL		iv	22.1	-16.3	cyclosporine	15647416	iv	-20	-2	
60-80-0	antipyrine	0.038		7075648	1.0	PL	NO	YES	Not specified	PL		po	180.4	-65	loroxicam	1683552	po		177.7	
503612-47-3	apixaban	0.34		PL	0.5	PL	YES	YES	CYP3A4, CYP1A2, CYP2C8	PL	BCRP, P-gp	po	98.8		ketoconazole	ELIQUIS PL	po	2.8	9.3	
74863-84-6	argatroban	0.16		PL			NO	YES	Not specified	PL		iv	0.3	-2.1	erythromycin	NDA 20883	iv		168.5	
129722-12-9	aripiprazole		<0.01 (total radioactivity)	PL	0.87	PL	NO	YES	CYP2D6, CYP3A4	PL		po	136.1	-59	paroxetine	21739267	po	33.4	16.9	
1327-53-3	arsenic trioxide	0.15		PL			NO	YES	Methyltransferase	PL					No DDI Study with AUC or CL Change in DIB					
65576-45-6	asenapine		0 (sublingual)	PL	0.35 (sublingual);	PL	NO	YES	CYP1A2, UGT1A4	PL		sl	30.3	-20.4	fluvoxamine	NDA 022117	sl	24.4	25.3	
83015-26-3	atomoxetine		0.03	PL	0.63 (EM); 0.94 (PL)	PL	NO	YES	CYP2D6	PL		po	605.7	-84.8	paroxetine	12412820	po		65.7	
330784-47-9	avanafil		0	NDA 202276			NO	YES	CYP3A, CYP2C	PL		po	1183.2		ketoconazole	NDA 202276	po	3.8	11.2	
319460-85-0	axitinib		not detected	PL	0.58	PL	NO	YES	CYP3A, CYP1A2, CYP2C19	PL	BCRP, OATP1B	po	105.8		ketoconazole	20740300	po	-21.8	94.9	
147403-03-0	azilsartan		0.15	PL	0.6	PL	NO	YES	CYP2C9	PL	P-gp	po	40		fluconazole	NDA 200796	po	29.7		
149908-53-2	azimilide- not approved in USA		0.49 (total radioactivity)	16052551			NA	YES	CYP3A, CYP 1A, FMO	16052551		po	16	-8.3	ketoconazole	15563362	po	13.9	-3.9	
843663-66-1	bedaquiline		<0.001	PL			NA	YES	CYP3A4	PL		po	22		ketoconazole	NDA 204384	po		-19	
202189-78-4	bilastine- not approved	0.66	0.42	23529786	0.607	23529786	YES	YES	CYP3A	DIBD	OAT3, P-gp	po	81.7	-47.5	ketoconazole	21642470				
394730-60-0	boceprevir		0.03	PL			NA	YES	AKR, CYP3A	PL	BCRP, P-gp	po	119.9		ketoconazole	NDA 202258	po	-13.9	1.5	
179324-69-7	bortezomib						NA	NA	CYP3A4, CYP2C19, CYP1A2	PL		iv	35.2		ketoconazole	20110052	iv	-12.9	62.8	
380843-75-4	bosutinib		0.03 (total radioactivity)	PL			NA	YES	CYP3A4	PL	P-gp	po	714.6	-89.6	ketoconazole	21148045	po	116.6	104.6	
357336-20-0	brivaracetam		0.95 (total radioactivity)	17199019	>0.90	17199019	NO	YES	CYP2C8	PL		po	-5.3	5.8	gemfibrozil	22538270	po	50.2	57.2	
34911-55-2	bupropion		0.005	PL			NA	YES	CYP 2B6	PL	BCRP, P-gp	po	61.1	-44.1	ticlopidine	15961986	po		57.3	
58-08-2	caffeine	0.0121		3986081	1.0	6832208	NO	YES	CYP 1A2	DIBD		po	1271.5	-91.3	fluvoxamine	16236038	po	-9.7 [MR]	-77.4 [MR]	
842133-18-0	canagliflozin		<0.01	PL	0.65	PL	NO	YES	UGT1A9, UGT2B4	PL	P-gp	po	21		probenecid	NDA 204042	po	7.3	6.5	
139481-59-7	candesartan	0.59	0.33	NDA 020838	0.42	NDA 020838	YES	YES	Not specified	PL	P-gp	po	13.8		hydrochlorothiazide	2212817	po		22.7	
154361-50-9	capecitabine		0.03	PL			NA	YES	Not specified	PL		po	133.5		sorafenib	21209247	po		47.6	
194085-75-1	carisbamate		0.02	17116021	0.94	17116021	NO	YES	UGT	19453703		po	7	-7.2	valproic acid	17381436	po	15.4	107.7	
414910-27-3	casopitant- not approved	<0.01		19420128	0.93	19420128	NO	YES	CYP 3A4	DIBD		po	1106.3		ketoconazole	20124517	po	12.1	22.1	
162808-62-0	caspofungin		0.014	PL			NO	YES	Not specified	PL	OATP1B1	iv	61.3		rifampin (OATP1B1)	15504857	iv	54.5	76.1	
288383-20-0	cediranib- not approved in USA						NA	NA	UGT1A4, FMO1	DIBD	P-gp	po	21.3		ketoconazole	23196640	po		11.6	
56796-20-4	cefmetazole	0.9		Interview form (Japanese)			YES	NO	Not metabolized	Interview form	OATP1B3	iv	58	-35.5	probenecid	2729930				
189345-04-8	ceftaroline	0.64		PL			YES	YES	Phosphatase, hydrolysis	PL		iv	-2.7	2.1	avibactam	23295928				
68401-81-0	ceftizoxime	0.57 - 0.93		3861322			YES	NO			OAT3, OAT3	iv	59.2	-39.5	probenecid	6311785				
145599-86-6	cerivastatin		<0.02	PL	0.6	PL	NO	YES	CYP3A4, CYP2C8	PL	BCRP, OATP1B	po	375.3		cyclosporine	10096257				
533-45-9	chlormethiazole	<0.01	<0.01	709096	0.15	1233235	NO	YES	CYP2A6	DIBD		po		-30.8	cimetidine	7333351	iv	-11.7	-50	
95-25-0	chlorzoxazone		<0.01	PL			NA	YES	CYP2E1, CYP1A2	7550365		po	691.8	-89.9	disulfiram	10579149	po	-26.5 [MR]	-74.7 [MR]	
113852-37-2	cidofovir	0.8 - 1.0		PL			YES	NO	Not specified	PL	OAT1, OAT3	iv	78.4	43.5	probenecid	7574510				
73963-72-1	cilostazol		<0.02	PL			NA	YES	CYP3A4, CYP2C19	PL		po	72.4	-41.2	erythromycin	10702888	po		2.6	
226256-56-0	cinacalcet	<0.01		15328250	0.20-0.25	19566113	NO	YES	CYP3A4, CYP2D6, CYP1A2	PL		po	102.9	-64.7	ketoconazole	17518508	po	2.8	144.2	
85721-33-1	ciprofloxacin	0.83	0.40 - 0.50	3209529, PL	0.7	PL	YES	NO	Not specified	PL	BCRP, P-gp	iv	74.7	-41.2	probenecid	7586947				
59729-33-8	citalopram	0.1		PL	0.8	PL	NO	YES	CYP3A4, CYP2C19	PL	P-gp	po	41.2	-29.9	cimetidine	9218934	po			
81103-11-9	clarithromycin		0.2-0.4	PL	0.50	PL	YES	YES	3A4	DIBD	P-gp	po	77.2		ritonavir	9797791	po		0	
105956-97-6	clinafloxacin	0.75	0.64	11502525	0.9	11502525	YES	NO	Not specified	PL		po			No DDI Study with AUC or CL Change in DIB					
22316-47-8	clobazam		0.02	PL			NA	YES	CYP3A4, CYP2C19, CYP2B6	PL	P-gp	po	47.5		ketoconazole	22422635	po			
1004316-88-4	cobicistat (GS-9350)		0.083 (total radioactivity)	PL			NA	YES	CYP3A, CYP2D6	PL	BCRP, OCT2, P-gp	po	16.9		atazanavir	NDA 203100	po		0.6	
210101-16-9	conivaptan	0.01		PL	0.44	10638391	NO	YES	CYP3A	PL	P-gp	po	98.2		ketoconazole	NDA 021697	iv	11.9	80.1	
50-18-0	cyclophosphamide	0.10 - 0.20		PL	0.74		NO	YES	CYP2A6, CYP2B6, CYP3A4/5	PL		iv	76.8	-34.5	busulfan	10800057	iv		-28.9	
211914-51-1	dabigatran	0.8	<0.05	20214409, 1750	0.06 - 0.07	20214409	YES	NO	Hydrolysis, UGT	PL		po	142.5		verapamil	22946890	po		-1.6	
461432-26-8	dapagliflozin		<0.02	PL	0.78	PL	NO	YES	UGT1A9	PL	P-gp	po	50.7	-35.3	mefenamic acid	23061428	po	3.2	35.9	
206361-99-1	darunavir		0.077	PL	0.37	PL	NO	YES	CYP3A	PL	OATP1B1, P-gp	po	969.5		ritonavir	19131522	po	-8.4	20	
1131-64-2	debrisoquine						NO	YES	CYP2D6	DIBD	OCT1	po	-10.8	1.7	peginterferonalpha-2a	22765278	po	-15.4 [MR]	-84.6 [MR]	
100643-71-8	desloratadine (descarboethoxylopratadine)	0.44 (total radioactivity)		PL			NA	YES	Not specified	PL	P-gp	po	20.9		ketoconazole	12169045	po		8.4	

93413-62-8	desvenlafaxine (O-desmethylvenlafaxine)	0.45	PL	0.8	PL	YES	YES	UGT, CYP3A4	PL		po	42.4	-29	ketoconazole	NDA021992	po	4.3	41	
113775-47-6	dexmedetomidine	0	PL			NO	YES	UGT, CYP2A6	PL			No DDI Study with AUC or CL Change in DIB				iv			
439-14-5	diazepam	0	1981543	0.98	6747022	NO	YES	CYP2C19, CYP3A4	PL		po	224.1		grapefruit juice	9625273	iv			
69655-05-6	didanosine (2,3-dideoxyinosine)	0.18		0.42	PL	YES	YES	Endogenous purine elimination	PL		po	82.5		ganciclovir	9495222				
118457-15-1	d-nebivolol	0	NDA021742			NO	YES	UGT, CYP2D6	PL		po	726.5	-86.4	fluoxetine	NDA 021742	po		883.7	
120014-06-4	donepezil	0.17	PL			NA	YES	CYP2D6, CYP3A4, UGT	PL		po	35.9		ketoconazole	9839763	po		47.6	
148016-81-3	doripenem	0.71	PL			YES	NO	Dehydropeptidase-I	PL		iv	74.6	-43.6	probenecid	NDA 22106				
74191-85-8	doxazosin	Trace	PL	0.65	PL	NO	YES	CYP3A4, CYP2D6, CYP2C19	PL		po	-16.6		nifedipine	8491245	po	43		
141626-36-0	dronedarone	0	PL	0.15 (with high fat)	PL	NO	YES	CYP3A4	PL		po	2383.3		ketoconazole	NDA 020425	po		75	
67392-87-4	drosipirone	0	11024226	0.76	11024226	NO	YES	Non P450 metabolism, CYP	PL		po	97.9	-49.9	boceprevir	NDA 202258	po		197.4	
116539-59-4	duloxetine	<0.01	PL	0.43	Goodman & G	NO	YES	CYP1A2, 2D6	PL		po	460	-77.2	flvoxamine	18307373	po		177.6	
90729-43-4	ebastine	0.001	Interview form (Japanese)			NA	YES	CYP 2J2 , CYP 3A4	Interview form (Japanese)		po	4149.8		ketoconazole	15752381	po	72.4	41.6	
697761-98-1	elvitagravir (GS-9137)	0.067 (total radioact)	PL			NA	YES	CYP3A, UGT1A1/3	PL	P-gp	po	1888.3	-95	ritonavir	NDA 203100	po		40.1	
87233-61-2	emedastine	0.036	PL			NA	YES	Not specified	PL		po	33.7	-22.2	ketoconazole	11396749				
75847-73-3	enalapril	0.18	6289858			NA	YES	Carboxylesterases	Interview form	OATP1B1	po	50		probenecid	2158548	po		57	
76420-72-9	enalaprilat	0.88	Goodman & Gil	0.41 (po enalapril)	Goodman & G	YES	NO	Not specified	PL			No DDI Study with AUC or CL Change in DIB							
159519-65-0	enfuvirtide			0.843 (sq)	PL	NA	NA	Not specified	PL		sq	23.7		ritonavir	15199084				
915087-33-1	enzalutamide	0.004	NDA203415			NA	YES	CYP2C8, CYP3A4	PL		po	325.5		gemfibrozil	NDA 203415	po	4.9	29.2	
107724-20-9	eplerenone	0.0165	PL	0.69	PL	NO	YES	CYP3A4	PL		po	438.7		ketoconazole	15204695	po		44.5	
133040-01-4	eprosartan	0.37	9737815	0.13	9737815	YES	YES	Not metabolized	PL		po	4		fluconazole	9357393	po		61.5	
253128-41-5	eribulin	0.082	PL			NO	YES	Not metabolized	PL		iv	1	8.7	ketoconazole	22555773	iv	83.4	214.8	
183321-74-6	erlotinib	0.003	PL	0.59	16490804	NO	YES	CYP1A1, CYP1A2, CYP3A4	PL	BCRP, P-gp	po	68.8	-35.4	ketoconazole	108000659	po		4.1	
114-07-8	erythromycin (po)	0.12	Goodman & Gil	0.32	7724478	NO	YES	CYP3A	Interview form	BCRP, OATP1B1	iv		-72.9	troleandomycin	12426516				
114-07-8	erythromycin (iv)	0.12	Goodman & Gilman, 12th ed.			NO	YES	CYP3A	Interview form	BCRP, OATP1B1	iv					iv			
104746-04-5	eslicarbazepine	0.31	18397682			YES	YES	UGT	PL		po	-7.2	9.7	topiramate	20377319	po		3.5	
33419-42-0	etoposide	0.25	PL	0.48-0.57	3975657	NO	YES	CYP3A4, UGT, SULT	PL	BCRP, OATP1B1	iv	89.6	-45.5	valsopodar	8636778	iv			
202409-33-4	etoricoxib - not approved	0.003	0.003	12527704	0.83	12527704	NO	YES	CYP3A4, CYP2C9, CYP2D6, 4	12527704	iv	69		miconazole	18777173	iv	21.4	89.9	
269055-15-4	etravirine	0	PL			NO	YES	CYP3A4, CYP2C19, CYP2C9	PL		po	87		fluconazole	23400742	po	-10.3	-10.7	
159351-69-6	everolimus	0	PL			NO	YES	CYP3A4	PL	P-gp	po	1371.1	-93.3	ketoconazole	15831774	po	102.4	224.4	
107868-30-4	exemestane	<0.01	PL			NA	YES	CYP3A4, aldoaketoreductase	PL		po	-5.6		raloxifene	17952589	po		137.4	
144060-53-7	febusostat	0.03	PL			NA	YES	UGT1A1, UGT1A3, UGT1A9	PL		po	40.8	-27.6	S-naproxen	16855070	po	29.7	54.7	
25451-15-4	felbamate	0.4 - 0.5	PL			YES	YES	Not specified	PL		po		-37.3	gabapentin	8857758				
286930-02-7	fesoterodine	0.16 (5-HMT)	PL	0.52 (5-HMT)	PL	YES	YES	CYP 3A4, CYP2D6 (5-HMT)	PL		po (data of 5	131.2		ketoconazole	19347334	po (data of 5-HMT)		115.5	
83799-24-0	fezofenadine	0.35	20307657	0.3	20307657	YES	YES	Not specified	PL	MATE1, MATE2	po	384.3	-79.8	indinavir and ritonavir	19225389				
162359-55-9	finlimod	0	PL	0.93	PL	NO	YES	CYP 4F2	PL		po	69		ketoconazole	19118083	po	12.9	47.2	
79660-72-3	fioroxacin	0.62	0.65	3125788	1	3125788	YES	NO	Not specified		iv	No DDI Study with AUC or CL Change in DIB				iv			
86386-73-4	fluconazole	0.76		2850753	0.9	8448970	YES	NO	Not specified	PL	po	-12.9		cimetidine	2330488	iv		24.7	
21679-14-1	fludarabine	0.37	0.19	19862681	0.58	19862681	YES	YES	Not specified	PL	iv	1.9	2.2	busulfan	17211431				
90566-53-3	fluticasone	0.02	0.01	PL	0.139 (inhalation)	PL	NO	YES	CYP3A4	PL	P-gp	inh	35.7	-26.4	ketoconazole	23116485	inh	34.2	82.7
93957-54-1	fluvastatin	<0.02	PL	0.24	PL	NO	YES	CYP2C9, CYP2C8, CYP3A4	PL	BCRP, OATP1B1	po	254.7	-69.1	cyclosporine	11907637	po		150	
4428-95-9	foscarnet	0.95	Goodman & Gil	0.09	Goodman & G	YES	NO	Not specified	PL		iv	-5.8	2.7	probenecid	9056062				
135326-11-3	gadoxetic acid	0.57	Interview form (Japanese)			YES	YES	Not metabolized	Interview form	OATP1B1, OAT	iv	No DDI Study with AUC or CL Change in DIB				iv	57.5	31.3	
357-70-0	galantamine	0.2	0.2	PL	1	Goodman & G	NO	YES	CYP2D6, CYP3A4	PL	po	-4.6	-0.6	risperidone	12463729	po	-1.4	33.2	
82410-32-0	ganciclovir	0.91	PL	0.09	7585846	YES	NO	Not specified	PL	MATE1, MATE2	po	54.9		probenecid	9495222				
194804-75-6	garenoxacin-not approved in US	0.496	Interview form	0.92	Interview form	YES	YES	SULT, UGT	Interview form (Japanese)		po	6		omeprazole	17395892				
112811-59-3	gatifloxacin	0.82	10850521			YES	NO	Not specified	PL		po	10.3		rifampin (600 mg) + isoniazid (30	17951604	po		22	
184475-35-2	gefitinib	<0.04 (total radioactivity)	PL	0.6	PL	NO	YES	CYP 3A4	PL	BCRP, OATP1B1	po	80.2		itraconazole	16176119	po	39.9	263	
119914-60-2	grepafloxacin	0.066 - 0.095	9484872	0.72	9484872	NO	YES	SULT, UGT	9484872	BCRP	po	4.1	-3	warfarin	9433655	po	54.2	118.6	
58-93-5	hydrochlorothiazide	0.7	PL (amturide)	0.7	PL (amturide)	YES	NO	Not specified	PL		po		-78.3	valsartan	22122818				
466-99-9	hydromorphone	0.07 (route of admin)	PL	0.42	Goodman & G	NO	YES	UGT	PL		po	-6.2		ethanol	18062845	po		272.4	
127-07-1	hydroxyurea	0.36	0.37	9473217	1.08	9473217	YES	YES	Not specified	PL	po	No DDI Study with AUC or CL Change in DIB				DROXIA PL			
114084-78-5	ibandronate	0.5 - 0.6	PL	0.006	PL	YES	YES	Not metabolized	PL		iv	-0.7	0.9	tamoxifen	NDA 021455				
133454-47-4	loperidone	0.007	NDA 022192			NA	YES	CYP2D6, CYP3A4	PL		po	131.4		fluoxetine	NDA 022192	po	25.7	-31.9	
152459-95-5	imatinitib	0.05	NDA 21335	0.983	Goodman & G	NO	YES	CYP3A4, CYP1A2, CYP2D6, 4	PL	BCRP, OATP1B1	po	38.2	-28.8	ketoconazole	15138710	po	-21.8	-34	
761423-87-4	ipragliflozin-not approved in US	0.01	Interview form	0.902	Interview form	NO	YES	UGT2B7, UGT2B4, UGT1A8	Interview form (Japanese)		po	-0.1	0.9	pioglitazone	22587345	po		29.8	
873054-44-5	ivacaftor	negligible	PL			NO	YES	CYP3A	PL	P-gp	po	745		ketoconazole	NDA 203188	po		92.4	
219989-84-1	ixabepilone	0.056	PL			NO	YES	CYP3A4	PL	P-gp	iv	79.1		ketoconazole	18451235	iv	22.2	30.3	
175481-36-4	icosamide	0.4	PL	1	PL	YES	YES	CYP3A4, CYP2C9, CYP2C19	PL		po	19.6	-16.4	omeprazole	24562729	po		61.3	
134678-17-4	lamiivudine	0.71	PL	0.86	PL	YES	NO	Not specified	PL	BCRP, MATE1, 1	po	46		BILR 355 and ritonavir	21128991	po		-3.4	
103577-45-3	lansoprazole	0	PL	0.91	8803522	NO	YES	CYP3A, CYP2C19	Interview form	P-gp	po	282.7	-75	flvoxamine	15496639	po	94.8	300.7	
231277-92-2	lapatinib	<0.02	PL			NA	YES	CYP 3A4, CYP3A5, CYP2C19	PL	BCRP, P-gp	po	266.8		ketoconazole	19371315	po		14	
571170-77-9	laropiprant	0.011	17431030	0.8	17431030	NO	YES	UGT	17431030		po	38.6		clarithromycin	20337634	po		177.5	
180916-16-9	lasofoxifene	0.0177	18372400			NA	YES	CYP3A4, CYP3A5, CYP2D6, 4	18372400		po	20.7		ketoconazole	16822276	po	-2.6	38.1	
191732-72-6	lenalidomide	0.74	PL			YES	NO	Not specified	PL	P-gp	po	No DDI Study with AUC or CL Change in DIB							
102767-28-2	levetiracetam	0.66	PL	1	PL	YES	NO	Not specified	PL		po	11.2	-10.3	valproic acid	12576167	po	-4.3	12	
141505-33-1	levosimendan-not approved in US		0.85	8907132	NA	NA	Not specified				po	48.8		digoxin	18793580	iv		16.5	
137-58-6	lidocaine	0.028	5010683	0.35	Interview form	NO	YES	CYP1A2, 3A4	Interview form (Japanese)		iv		-59.9	flvoxamine	14749694	iv			
668270-12-0	linagliptin	0.05	22568694	0.3	PL	NO	YES	Not metabolized	PL	OATP1B3, OCT	po	101.4		ritonavir	TRADIENTA PL	po	-24.8	-14.6	

165800-03-3	linezolid	0.31	0.35	12668582	1	PL	YES	YES	Not specified	PL		po	No DDI Study with AUC or CL Change in DIBD		?	no change		
204656-20-2	liraglutide		0 (sq)	PL	0.55 (sq)	PL	NO	NO	Not specified	PL		sq	-2.5	insulin	21114606	sq	-16.6	-13.9
76547-98-3	lisinopril	1		2547465	0.25 (oral)	2844083	YES	NO	Not metabolized	PL		po	13.1	digoxin	2853897			
98079-51-7	lomefloxacin		0.65	PL			YES	YES	Not specified	PL		po	11.9	fuorexime	8070509	po	no significant change (cirrh)	
182431-12-5	lomitapide		0	PL	0.07	PL	NO	YES	CYP3A4, CYP1A2, CYP2B6, CYP2C8	PL		po	2626.2	ketoconazole	NDA 203858	po	46.7	163.7
192725-17-0	lopinavir		0.022	PL			NA	YES	CYP3A4	PL	OATP1B1, P-gp	po	75.1	valproic acid	15504860	po	40.9	17.8
846-49-1	lorazepam		0.003	PL	0.9	PL	NO	YES	UGT	PL		iv		probenecid	4020675	iv		32.4
114798-26-4	losartan	0.12	0.042	8529329	0.33	PL	NO	YES	CYP2C9, CYP3A4	DIBD	P-gp	po	108.5	milk thistle	19221727	po		
367514-87-2	lurasidone		<0.09 (total radioact)	PL			NA	YES	CYP3A4	PL		po	830	ketoconazole	NDA 200603	po	45.4	57.5
89226-50-6	mandipine-not approved in US		0	Interview form (Japanese)			NO	YES	CYP3A4	Interview form (Japanese)		po	-10.5	delapril	14558436	po	15.1	156
376348-65-1	maraviroc		0.08	PL	0.23	PL	YES	YES	CYP3A4	PL	OATP1B1, P-gp	po	897.9	saquinavir and ritonavir	18333864	po	2.6	19.2
176161-24-3	maribavir-not approved in US		<0.02	12654667			NA	YES	CYP3A4	12654667		po	54	ketoconazole	18316526			
19982-08-2	memantine		0.48	PL			YES	YES	Not specified	PL	OCT2	po	5.7	donepezil	15266045			
59-05-2	methotrexate		0.85 (sq)	9951428	0.7	Goodman & G	YES	NO	Not specified	PL	BCRP, OAT1, O	iv		cotrimoxazole	638616			
235114-32-6	micafungin	0.012		PL			NO	YES	Arylsulfatase, CYP3A	PL		iv	13.2	cyclosporine	16027407	iv		-22.6
59467-70-8	midazolam (iv)		0	6138080			NO	YES	CYP3A4	PL		iv	686.8	ketoconazole	19302901	iv	33.5	92.1
59467-70-8	midazolam (po)		0	6138080	0.31 - 0.72	PL	NO	YES	CYP3A4	PL		po	2590.9	tipranavir and ritonavir	20147896			
92623-85-3	milnacipran		0.55	PL	0.85 - 0.90	PL	YES	YES	Not specified	PL		po	10	methothimeprazine	NDA 022256	po	2.8	45.8
223673-61-8	mirabegron		0.06-0.25	PL	0.29 - 0.35	PL	YES	YES	CYP2D6, CYP3A4	PL	P-gp	po	78.8	ketoconazole	23625188	po	25.2	61.3
862189-95-5	mirodenafil-not approved in US						NA	NA	CYP3A4, CYP2D6	20110038		po	389.3	ketoconazole	20110038			
151096-09-2	moxifloxacin		0.2	PL	0.9	PL	NO	YES	UGT, SULT	PL	P-gp	po	10.2	itraconazole	14756383	po	-22	2
24280-93-1	mycophenolic acid		0.03	PL	0.72	PL	NO	YES	UGT	PL		po	117.8	tacrolimus	19606088	po	-24.8	26.2
465-65-6	naloxone				0.009-0.02	22541841	NA	NA	UGT	PL		iv		No DDI Study with AUC or CL Change in DIBD for iv form		po		
16590-41-3	naltrexone		0.02	PL	0.2	Goodman & G	NO	YES	Not specified	PL		iv/im		No DDI Study with AUC or CL Change in DIBD for iv/im forms		im	6.1	-3.7
118457-14-0	neбиволol (racemic)	0	0	NDA 021742			NO	YES	UGT, CYP2D6	PL		po	557.1	fluoxetine	20489028	po		611.2
83366-66-9	nefazodone		<0.01	PL	0.23	8825195	NO	YES	CYP3A4	DIBD		po	44.7	lorazepam	8748429	po		99
159989-64-7	nefinavir		0.01 - 0.02	PL	0.88 (single dose)	16172185	NO	YES	CYP3A, CYP2C19	PL	P-gp	po	146.2	nevirapine	12949316	po	13.4	62.6
641571-10-0	nilotinib		0	NDA 022068			NO	YES	CYP3A4	NDA 022068	OATP1B1, OAT	po	210.6	ketoconazole	20702754	po	33.3	36.5
70458-96-7	norfloxacin		0.26 - 0.32				NA	YES	Not specified	PL	BCRP			No DDI Study with AUC or CL Change in DIBD		po		0.2
82419-36-1	ofloxacin		0.63	3481317	0.98	PL	YES	YES	Not specified	PL	BCRP	po	15.8	probenecid	18370547			
144689-24-7	olmesartan	0.36	0.095	11361048	0.26	PL	YES	YES	Not metabolized	PL	OAT1, OAT3, O	po	21.1	pravastatin	18641915	po	30.4	47.8
73590-58-6	omeprazole		negligible	2315973	0.39	2315973	NO	YES	CYP2C19, CYP3A4, CYP2C8	DIBD	P-gp	po	529.3	fluconazole	11932962	po	69	171
99614-02-5	ondansetron		0.05 (route of admin)	PL	0.65	10876746	NO	YES	CYP3A4, CYP1A2, CYP2D6	PL		iv	14.8	aprepitant	12867217	iv	126.9	59.9
187227-45-8	oseltamivir carboxylate	0.93	0.75	10628898	0.8	10628898	YES	NO	Not specified	PL		po (oseltamivir)	151.7	probenecid	11744606	po (oseltamivir)		-6.3
128607-22-7	ospremfene		<0.02				NA	YES	CYP3A4, CYP2C9, CYP2C19	PL		po	178.2	fluconazole	23852652	po	-7.5	42.5
61825-94-3	oxaliplatin			PL			NA	NA	Nonenzymatic	PL	MATE1, MATE2	iv	39	regorafenib	NDA 203085	iv	↔	-8.9
144598-75-4	paliperidone (9-hydroxyrisperidone)		0.59	PL	0.28	PL	YES	NO	CYP2D6, CYP3A4	PL	P-gp	po	18	paroxetine	19585395	po		-27.3
102625-70-7	pantoprazole	0	0	PL	0.77	PL	NO	YES	CYP2C19, CYP3A4	PL	P-gp	po	12	clarithromycin	14998561	po		-15.4
131918-61-1	paricalcitol		0	PL	0.72 - 0.86	PL	NO	NO	CYP 24, CYP 3A4, UGT 1A4	PL		po	3	omeprazole	17173278	iv	12.1	-31.9
396091-73-9	pasireotide		0.06 (sq)	PL			NA	YES	Not metabolized	PL	P-gp	sq	5	vildagliptin	NDA 200677	sq	12.5	56.4
444731-52-6	pazopanin		0.001	23548165	0.214	23548165	NO	YES	CYP3A4, CYP1A2, CYP2C8	PL	OATP1B1, OAT	po	65.4	ketoconazole	23636448	po		
215647-85-1	peginterferon alpha-2b		0.3 (route of admin)	PL			YES	YES	Not specified	PL		sq	12.1	ribavirin	10960463			
380917-97-5	perampanel		<0.0012	NDA 202834	1	NDA 202834	NO	YES	CYP3A, CYP1A2, CYP2B6	PL		po	20	ketoconazole	NDA 202834	po	50	155
57-41-0	phenytoin		0.02 (route of admin)	Goodman & Gil	0.864	21233690	NO	YES	CYP2C9, CYP2C19, CYP1A2	PL		po	133.1	piperine	11808866	iv		-19
111025-46-8	pioglitazone		negligible	PL			NO	YES	CYP2C8, CYP3A4, CYP1A1	PL		po	366.4	gemfibrozil	22625877			
147511-69-1	pitavastatin		0.03	NDA 022363	0.51	PL	NO	YES	CYP2C9, CYP2C8, UGT1A3	PL	BCRP, OATP1B1	po	428.4	rifampin SD	23831870	po	57	275.1
171228-49-2	posaconazole		<0.002	PL	0.54	PL	NO	YES	UGT	PL	P-gp	po		No DDI Study with AUC or CL Change in DIBD		po	35.5	15.2
150322-43-3	prasugrel		0 (R-138727)	17403916			NO	YES	Not specified (R-138727)	PL		po	7	ketoconazole	17361128	po (data of R-138727)		8.1
81093-37-0	pravastatin	0.47	0.08	2106337	0.18	2106337	YES	YES	Not specified	PL	BCRP, OAT3, O	po	2183.5	cyclosporine	8356729			
148553-50-8	pregabalin		0.9	23205518	>0.90	PL	YES	NO	Not metabolized	PL		po	15.3	valproic acid	16146435			
111974-69-7	quetiapine		<0.01	PL	0.09	Goodman & G	NO	YES	CYP3A4	PL		po	520.4	ketoconazole	16390352	po		55.6
117976-89-3	rabeprazole		0.00	PL	0.52	PL	NO	YES	CYP3A4, CYP2C19	PL		po	181.9	fluvonaxime	16487224	po		119.5
84449-90-1	raloxifene		<0.002	PL	0.02	PL	NO	YES	UGT	PL	P-gp	po	7.6	exemestane	17952589	po		149.7
518048-05-0	raltegravir		0.09	PL			NA	YES	UGT1A1	PL	BCRP, OAT1, P-gp	po	210.9	omeprazole	19143531	po		-14.5
87333-19-5	ramipril		<0.02	PL	0.28	Goodman & G	NO	YES	Esterase, UGT	PL		po	21.7	aliskiren	17073832			
87269-97-4	ramiprilat		0.13	Goodman & Gil	0.48	Goodman & G	NO	YES	UGT	PL		po (ramipril)	0.11	vildagliptin	17986525			
95635-55-5	ranolazine		0.05	PL	0.5	16640453	NO	YES	CYP3A4, CYP2D6	PL	P-gp	po	264.3	ketoconazole	15778423	po	4	75.7
136236-51-6	rasagiline		<0.01	PL	0.36	PL	NO	YES	CYP1A2, UGT	PL		po	82.9	ciprofloxacin	NDA 021641	po	93.5	652.8
71620-89-8	reboxetine	0.0923	0.0838	10086838	0.91 - 1.02	10086838	NO	YES	CYP3A4	10534319		po	58.2	ketoconazole	10546921			
755037-03-7	regorafenib		0	NDA 203085			NO	YES	CYP3A4, UGT1A9	PL		po	33	ketoconazole	NDA 203085	po	-18	1
135062-02-1	repaglinide		0.001	PL	0.625	9877000	NO	YES	CYP2C8, CYP3A4	PL	P-gp	po	1830.4	gemfibrozil and itraconazole	12687332	po		302
150812-12-7	retigabine (ezogabine)		0.36	PL	0.6	PL	YES	YES	UGT, acetylation	PL		po	45.5	oral contraceptives	NDA 022345	po	-15.6	45.3
36791-04-5	ribavirin	0.17	0.044	2737800	0.326	2737800	NO	YES	Not specified	PL		po	-23.4	dipyrnadole	23459628	po	-14	-6.5
500287-72-9	rilpivirine		<0.01	PL			NA	YES	CYP3A	PL		po	140.4	darunavir/ritonavir	NDA 202022	po	49	8.9
106266-06-2	risperidone	0.03		Goodman & Gil	0.7	PL	NO	YES	CYP2D6	PL	P-gp	po	315.3	fluoxetine	11985287	po		52.8
155213-67-5	ritonavir		0.035 (oral)	PL			NA	YES	CYP3A	PL	P-gp	po	382.6	artesunate and pyronaridine	22403324	po		
366789-02-8	rivaroxaban	0.36		PL	0.8-1.0	PL	YES	YES	CYP 3A4, CYP 2J2	PL	BCRP, P-gp	po	157.6	ketoconazole	23305158	po	15.2	131.5
143558-00-3	rocuronium	0.11		1443743			NO	YES	Not specified	PL		iv		propofol	11927473	iv		18.6

162401-32-3	roflumilast		0	PL	0.8	PL	NO	YES	CYP 1A2, CYP 3A4.	PL		po	155.4	-61	fluvoxamine	17596106	po	51	92.3	
84057-95-4	ropivacaine	0.01		PL			NO	YES	CYP 1A2	PL		iv	452.5	-85.5	erythromycin and fluvoxamine	10049910	iv			
122320-73-4	rosiglitazone	0	0.0001	PL	10859151	0.99	10859151	NO	YES	CYP 2C8, 2C9	PL		po	129		gemfibrozil	12898007			
287714-41-4	rosuvastatin	0.28		PL	0.2	PL	NO	YES	CYP2C9	PL	BCRP, OAT3, O	po	608.2		cyclosporine	15289793	po	4.9	20.8	
99755-59-6	rotigotine		<0.01 (transdermal)	PL			NA	YES	CYP, SULT, UGT1A9, UGT2B	PL		transdermal	0.8		levodopa and carbidopa	19628729	transdermal		-9.5	
169939-94-0	ruboxistaurin (LY333531)		<0.01	PL	16896067		NA	YES	CYP3A4	DIBD					No DDI Study in DIBD					
106308-44-5	rufinamide		0.02	PL			NA	YES	CES	PL					No DDI Study with AUC or CL Change in DIBD					
941678-49-5	ruxolitinib		<0.01	PL			NA	YES	CYP3A4, CYP2C9	PL		po	91.2	-47.9	ketoconazole	21602517	po	87	28	
361442-04-8	saxagliptin		0.24	PL	0.5	22823746	YES	YES	CYP3A4, CYP3A5	PL	P-gp	po	266.6		ketoconazole	NDA 022350	po	9.6	38.2	
14611-51-9	selegiline	0.01		PL	7995016	0.04	17715422	NO	YES	Not specified	PL		po	4400		oral contraceptives	10215747, ELDEPRY	po		1693.6
139755-83-2	sildenafil		<0.02	NDA 022895	0.41	11879254, PL	NO	YES	CYP3A4, CYP2C9	PL	BCRP, P-gp	po	889.4		ritonavir	10930961	po		84.5	
160970-54-7	silodosin		<0.04	PL	16518089	0.32	PL	NO	YES	UGT2B7, ADH/ALDH, CYP3A4	PL	P-gp	po	208.6		ketoconazole	NDA 22206	po		-23.9
53123-88-9	sirolimus		0.022 (total radioactivity)	PL	0.14	PL	NO	YES	CYP3A4, CYP3A5	DIBD	OATP1B1, OAT3	po	2512.3		telaprevir	23408534	po	48.4	95.8	
486460-32-6	sitagliptin		0.79	NDA 021995	0.87	PL	YES	NO	CYP3A4, CYP2C8 (limited m	PL	OAT3, P-gp	po	53.9	-35.7	gemfibrozil	22173280	po		21.1	
242478-37-1	sofinacin	0.0738		PL	15293866	0.88	15293866	NO	YES	CYP 3A4	PL		po	94.4		ketoconazole	16867168	po		39.1
110871-86-8	sparfloxacin		0.10	PL	0.92	PL	NO	YES	UGT	PL	P-gp	po	-11.4		cimetidine	8688981				
83647-97-6	spirapril - not approved	0.16			0.5	8061850	NA	NA	Esterase			po	1.9		hydrochlorothiazide	12872612				
83602-05-5	spiraprilat - not approved	0.755			0	(spirapril po vs s	8061850	NA	NA	Not specified		po (spirapril)	9.6		hydrochlorothiazide	12872612				
3056-17-5	stavudine		0.42	PL	0.864	PL	YES	YES	Limited metabolism	PL		po	9		emtricitabine	17526857				
68373-14-8	sulbactam	0.888		PL	3348612		YES	NO	Not specified	PL		iv	5		ceftriaxone	20686332				
557795-19-4	sunitinib		0.16 (total radioactivity)	NDA 021938 & 021968			NA	YES	CYP 3A4	PL	BCRP, OATP1B1	po	81.5	-46.2	ketoconazole	NDA 021938	po	10.6	7.9	
104987-11-3	tacrolimus	< 0.01		PL	11180035	0.188	11180035	NO	YES	CYP3A4	PL	P-gp	po	7697.6	-98.5	telaprevir	21618566	iv		
171596-29-5	tadalafil		< 0.003	NDA 21368			NA	YES	CYP3A4	PL		po	311.5		ketoconazole	NDA 021368	po	-1.1	-30.5	
57460-41-0	talinalol-not approved	0.53		PL	8527689	0.55	8527689	NA	YES	Not specified	PL	P-gp	po	54.4	-33.8	curcumin	22725660			
106133-20-4	ramlosin		0.087	PL	8810034	1	9344174	NO	YES	CYP3A4, CYP2D6	PL		po	183.5	-64.6	ketoconazole	21496064			
175591-23-8	tapentadol		0.03	PL	0.32	PL	NO	YES	UGT, CYP2C9, CYP2A19, CYP2D6	PL		po	49.5		probencid	NDA 22304	po	85.6	355.6	
197922-42-2	teduglutide				0.88 (sg)	PL	NA	NA	Not specified	PL					No DDI Study with AUC or CL Change in DIBD		sq		-10.5	
402957-28-2	telaprevir		0.011	NDA 201917			NO	YES	CYP3A4	PL	P-gp	po	219.8		ritonavir	NDA 201917	po	-16.3	-36.4	
372151-71-8	telavancin	0.62		NDA 022110			YES	YES	Not metabolized	NDA 022110		iv	4.8	-5.6	aztreonam	19443680	iv		-16.3	
3424-98-4	telbivudine		0.42	PL			YES	YES	Not metabolized	PL		po	5.6	-7.2	lamivudine	16801406	po	9.8	43.1	
191114-48-4	telithromycin		0.13	PL	0.57	12476037, PL	NO	YES	CYP3A4, non CYP-depende	PL	P-gp	po	61.7		itraconazole	15767219	po		9.9	
144701-48-4	telmisartan	0.009 (total radioactivity)		PL	11185629	0.42 - 0.58	PL	NO	YES	UGT	OATP1B3	po	132.3	-54.2	nisoldipine	17322141, MICARD	po		207.3	
162635-04-3	temsirolimus	0.046 (total radioactivity)		PL	0.015 - 0.025	19415181	NO	YES	CYP 3A4	PL	P-gp	iv	12	-10.5	ketoconazole	18458675		9.9		
147127-20-6	tenofovir	0.70 - 0.80		PL	0.25	PL	YES	NO	No metabolism by CYP	PL	OAT1, OAT3, P-gp	po	35.8	-23.6	ritonavir + ARV	14693529	po		19.7	
59804-37-4	tenoxicam-not approved	0.01		PL	6336292	1	6336292	NO	YES	CYP2C9	19514967	po	4.9	-6.6	probencid	8148224				
163451-81-8	teriflunomide	0.00147		NDA 202992	1	NDA 202992	NO	YES	Not specified	PL	BCRP, P-gp				No DDI Study with AUC or CL Change in DIBD		po	-1.7	-11.3	
58-46-8	tetrabenazine	0		PL			NO	YES	Carbonyl reductase, CYP2D6	PL		po	300		paroxetine	NDA 021894	po		39.5	
180384-57-0	tezosentan-not approved	0.05		PL	12745875		NO	YES	Not metabolized	12745875		iv	296.3	-74.8	cyclosporine	12136369				
115103-54-3	tiagabine		0.02	PL	0.9	PL	NO	YES	CYP 3A	PL		po	7.9		triazolam	10366992	po	59.9	70.4	
274693-27-5	ticagrelor		0.01	PL	0.36	PL	NO	YES	CYP 3A4	PL	P-gp	po	632		ketoconazole	022433	po	50.7		
220620-09-7	tigecycline	0.22		PL			NO	YES	Biliary excretion, UGT	PL		iv	5.8	6.1	digoxin	NDA 021821	iv	2.3	50.3	
192185-72-1	tipifarnib-not approved in US		< 0.1	PL	17302532	40.9 - 46.3	16988200	NO	YES	UGT, CYP3A4	16988200	po	23.5		gemcitabine	14581347	po	84.7	29.2	
110101-66-1	tirilazad			PL			NA	YES	CYP3A4	9021439		po	308.6	-77.6	ketoconazole	8627582	iv	110.6		
51322-75-9	tizanidine	0.03		PL	0.4	PL	NO	YES	CYP1A2	NDA 020397		po	3172.7		fluvoxamine	15060511				
143343-83-3	toborinone-not approved	0.34 - 0.50		PL	8163718		YES	YES	CYP2D6, CYP1A2	12017343		iv	-4.9		theophylline	12017343	iv		45.9	
375823-41-9	tocilizumab (atlizumab)						NA	NA	Not specified	PL		sq	13.9		rHuPH20	23547949				
477600-75-2	tofacitinib		0.288	PL	24464803	0.74	PL	YES	YES	CYP3A4, CYP2C19	PL	P-gp	po	103.2		ketoconazole	NDA 203214	po	3.2	64.6
150683-30-0	tolvaptan		0.002	NDA 022275	0.56	22257581	NO	YES	CYP3A4	PL	P-gp	po	439.7	-82.8	ketoconazole	21988334	po			
123948-87-8	topotecan	0.508		PL	0.3	8630291	YES	NO	pH-dependent hydrolysis	PL	BCRP, MATE1, P-gp	po	142.9		elacridar	12089223	iv			
89778-26-7	toremifene	negligible		Goodman & Gilman, 12th ed.			NO	YES	CYP3A4, CYP2D6	PL, 21380606					No DDI Study with AUC or CL Change in DIBD		po		56.7	
97322-87-7	troglitazone	0		PL	0.40 - 0.50	10496299	NO	YES	SULT, UGT	10496299		po	1.3		acetaminophen	9753210	po		46.6	
99-66-1	valproic acid	0.018	<0.03	PL	6411107, PL	0.928	6804223	NO	YES	UGT, Mitochondrial β-oxid		po	107.9	-54.4	felbamate	8603632				
137862-53-4	valsartan	0.29	0.073 (capsule), 0.13 (tablet)	PL	9174680	0.25	PL	NO	YES	CYP2C9	PL	OATP1B1, OAT3	po	34.1		hydrochlorothiazide	20852001	po	120.8	114.2
443913-73-3	vandetanib		<0.05	NDA 022405			NA	YES	CYP3A4, FMO1, FMO2	PL	OATP1B1, OAT3	po	16		itraconazole	22405	po	4.3	-5.7	
249296-44-4	varenicline		0.92	PL	0.9	PL	YES	NO	Not metabolized	PL	MATE1, MATE2	po	29.7	-21.9	cimetidine	17971819, CHANTIX PL				
86029-43-8	vecuronium	0.03 - 0.35		PL			NO	YES	Not specified	PL					No DDI Study with AUC or CL Change in DIBD		iv			
918504-65-1	vemurafenib		< 0.01	PL			NA	YES	CYP3A4	NDA 202429	OATP1B3, P-gp				No DDI Study with AUC or CL Change in DIBD		po			
306296-47-9	vicriviroc-not approved in US	0.47 (total radioactivity)		PL	21348539		NA	YES	CYP3A4, CYP3A5, CYP2C9	19492868		po	437.4		ritonavir	21348539				
60643-86-9	vigabatrin		0.8	PL	>0.90	PL	YES	NO	Not specified	PL		po	-5		ethanol	NDA 020427				
503068-34-6	vilanterol	0.70 (total radioactivity)		PL	<0.02	PL	NO	YES	CYP3A4	PL	P-gp	inh	90		ketoconazole	23116485, BREO EL	inh	-34.3	32.7	
163521-12-8	vilazodone		0.01	PL	0.72	PL	NO	YES	CYP3A4, CYP2C19, CYP2D6	PL		po	51		ketoconazole	NDA 022567	po	-2	-9	
274901-16-5	vildagliptin-not approved	0.33	0.21	PL	22339447	0.85	22339447	YES	YES	Hydrolysis	DIBD		po	11.6	-10.2	simvastatin	17931461	po	-18.6	-5.5
57-22-7	vincristine	<0.08		PL			NO	YES	CYP 3A4	PL	P-gp	iv	244.8	-68.6	nifedipine	2790693	iv		-4.5	
618385-01-6	vorapaxar (SCH 530348)	<0.01		NDA 204886	1	PL	NO	YES	CYP 3A4, CYP2J2	PL		po	94.9		ketoconazole	23426761	po	1.1	-0.6	
137234-62-9	voriconazole (po)	<0.02		PL	0.96	PL	NO	YES	CYP2C19, CYP2C9, CYP3A4	PL		po	806.8	-86.4	ritonavir, in CYP2C19 PMs	16890574				
137234-62-9	voriconazole (iv)	<0.02		PL	0.96	PL	NO	YES	CYP2C19, CYP2C9, CYP3A4	PL		iv								
192939-46-1	ximelagatran-not approved	0.83	0.08	PL	12584156	0.2	12584156	YES	NO	CES	DIBD	P-gp	po	81.6		erythromycin	16455803	po		-5.7
7481-89-2	zalcitabine	0.8	0.6	PL	>0.8	PL	YES	NO	Not specified	PL	OAT1, OCT1, O	po	54.2	-37.2	probencid	8692740, HIVID PL				

139110-80-8	zanamivir	0.87		10429835	0.02	10429835	YES	NO	Not specified	PL		iv	-2		oseltamivir	21690287			
186497-07-4	zibotentan (ZD4054)-not approved in US	0.36		22014279			YES	YES	CYP3A4	19480550		po	26.6	-20.4	itraconazole	19480550	po	40.1	44.9
111406-87-2	zileuton		<0.005	PL			NA	YES	CYP1A2, CYP2C9, CYP3A4, UPL			po	-13.4		prednisone	8620666	po	106.6	107.9
146939-27-7	ziprasidone		<0.01	PL	0.6	PL	NO	YES	AO, glutathione reduction, UPL			po	33.4		ketoconazole	10771458	po	19.5	34.5
139264-17-8	zolmitriptan	0.33 - 0.37	0.095 - 0.18	9205817	0.41	9833595	YES	YES	CYP1A2	DIDB	P-gp	po	55.8		propranolol	9431839	po		81.1

Abbreviations

AUC: area under the concentration-time curve

AUCR: AUC ratio

BCRP: breast cancer resistance protein

CL: clearance

CP score: Child-Pugh score

CYP: cytochrome P450

DDI: drug-drug interaction

DDI: Drug Interaction Database

ESRD: end stage renal disease

F: absolute bioavailability

FDA: Food and Drug Administration

fe: fraction excreted unchanged into urine

GFR: glomerular filtration rate

iv: intravenous

MATE: multidrug and toxin extrusion

NDA: new drug application

OAT: organic anion transporter

OATP: organic anion transporting polypeptide

OCT: organic cation transporter

P-gp: P-glycoprotein

PMID: PubMed identification number

po: per os (orally)

Footnotes

*1: Classification by the study authors (mild, moderate, severe) was inconsistent with the FDA recommendations in some studies; in these instances, they were still reported as "mild, moderate, or severe groups"; units in mL/min.

*2: Studies with ESRD subjects on dialysis were conducted at off-dialysis period

44.6	2.2	-12	-25.1	23623756	po	28.8	59.7	90.9	112.3	-37.5	-41.7	-54.8	-58.6	21176719
	-40.7	-49.3	-68.2	NDA 021038	iv			23.6						11682398
		-48.1		1127104										
					po				368.3				-75.8	1510449
		-86.1		NDA 021742	po	-24.5	134.4	370.3		27.1	-47.6	-66.4		NDA 021742
				15496218	po		13.4	18.7			-14.2	-16.2		15496219
					iv	61	183	410.2	680.4	-38.1	-64.7	-80.4	-86.7	NDA 22106
	-30.4			10631624										
				NDA 022425	po	-19.4	-11.8							NDA 022425
		-46.7		NDA 021355	po	4.4	36.8			-4.1	-26.8			16855071
		-84.9		15726876	po				116.4				-53.7	20384393
				14748620	po	-5	-29	-14.5						17518511
		-23.3		NDA 203100	po			-24.7					32.4	NDA 203100
					po		110.7	119.3	45.5	-58.7		-75	-39.4	11396749
		-12.7		2165799										
					po (enalapril)		299.3	1248.8						8504625
					sq			61.9	43.3			-37.8	-27.7	18091608
				NDA 203415										
		-35.2		NDA 21437	po	-0.6	12.1	42.1	-8.2	-2.9	-18.2	-32.4	43.7	15951471
				9469680	po	-24.4	25.3	55.3		26.1	-36.1	-94		9549643
	-39.8	-59.3		NDA 201532										
		-23.3		21938545										
					po				130.8					20090676
		-62.7		3606934	iv				63.7				-34	20090676
		0		18157705	po	61.1	111.1	153.6		-38.2	-52.9	-61.8		18397682
		22.4		3697995	iv						-43.9			3697995
	-18	-48		14517196	po		-31.7	-6.4	-31.7					14681341
				20206790										
308.5	-40.2	-67.5	-69.3	23453404										
184.3				15014897	po		171.7	89.1						15014897
	-28	-12.7		16397288	po	48	48	76		-40.3	-36.4	-6.6		15662289
					po		62.7	72.2	112.7	-38		-43	-49.4	9241102
				20371737	po (data of	58.8	83	132.5		-36.1	-44.4	-56		19246724
					po				184.5				-63.1	19696225
107.5	-10.9	-28.6	-50	15778425, 16432266	po			59.2				-23.1		NDA 022527
		-55.9		1622175	iv		47.7	157.9	142.1		-41.1	-54.6	-58.9	2499248
				15676037	iv	15.2	177.1	267.2		-2.9	-40	-68.6		15151523
					iv		15.9	116.1			-17.1	-57.3		12449721
75				23200625	inh			-9						23200625
				NDA 020261	po	20.6	3.2	15.9	52.1	2.5	18	-13.9	-34.4	11865968
					iv					-37.6	-79.3	-79.8		10096579
61.9	-41.6	-18.7	-33	21623212	iv		48.1		464.4			-28.2	-82.8	21623212
72.1	0.6	-22.8	-44.3	11936568										
					po	79.7	255.9	796.8	1348.4	-38.1	-66.2	-88.8	-96.8	12189361
					po			50.6						17355746
5			-17.7	10850525										
166.3	-28.5	-72.5	-62.4	21487718										
	-35.3	-58.3		9433653	po	35.5	43.4	23.7		6.1	-27.6	9		9433654
					po		231.5	746.3						6873147
				11794005	po		84.1	344.2						11794004
					po	87.7	70.1	62.1	151.7	-49.5	-43.1	-27.7	-59.7	15778424
					iv	29.2	49.4	74.9		-25.9	-21.7	-36.2		17615253
	-33.5	18.8		NDA 022192	po			24.1				-19.1		NDA 022192
51	-17.8	-2.8	-21.5	18235115	po	51.8	100.9	66.7		-27.2	-45.6	43.7		18235116
				23733389										
		-48.8		NDA 203188										
81	-18.6	-18.4	-36.1	NDA 022065										
				NDA 22253	po	26.8	22.5	59		-21.1	-18.3	-37.1		NDA 22253
8.5				9696966	po		174.7	412.3			-63.6	-80	-89.2	9690945, 17662093(ESRD)
338.2	-26.9	-73.1	-84.6	8299672	po	107.1	24	4.1		-50	65.4	-19.2		8299672
				NDA 022052										
				20484612	po			58.9						19433974
	7.2	-27		16397281										
					po	25.6	185.2	286.8	424.1	-20.1	-64.8	-73.9	-80.9	17954615
154.3	-1.4	-12.6	-53.9	15961984	po	70	150	200		-43	-52	-65	-70	NDA 021035
		-16		18303124	iv			-36.5	-6.2			150	40	17328582
	-18.8		-65.2	14749694	iv						-18.4	-49.4	-6.9	17178261
0.5	32.5	16.8		NDA 201280	po	7.8	70.8	41.6	53.7	-7.8	-41.6	-29.5		NDA 201280

				NDA 021130	po		16.4	15.3	28.2		-2.2	-15.9	-19	12936973
-41.5	31.4	20.3	87.3	21175436	sq	-19.9	-6.4	-0.3	-3.2	26.6	3.8	-3.8	8.9	20002084
					po		12.8	352.8						2834209
hosis)				MAXAQUIN PL	po		22.9	236.6	647.7		-15.9	-66.4	-85.3	1316065
				NDA 203858	po				39.3					NDA 203858
	-23.7	-22		16490802										
		-21.9		9840212										
		-50		COZAAR PL	po		67.3							12817522
170.4	-31.2	-48.4		NDA 200603	po	53	96.3	105		-31.7	-46.8	-50.1		NDA 200603
				9707354										
	-2.6	-15.7		19812445	po			224	98.6					23835512
					po		4.8	-2.1		-9.8		5.3		17244772
					po	62.1	101	134.4						22863669
					im					-16.9	-20	-45.2		9613341
		11.2		16172179	iv		-3.9				11			16172179
	2.8	-60.5	-66.1	15951470; 23772874	iv								69.1	6638545
					po				9.7				9	19696225
60.5		-17.4	-35.3	NDA 022256	po	16.2	52	199		-14.18	-28	-65.45		NDA 022256
	↔	-40.5		23208320	po	38.2	77.8	122		-20.6	-29.8	-53.9		23208320
					po			7				-6.5		23006442
				AVELOX PL	po	-7.6	-17.6	1.3		8.7	21.7	-1.1		11874385
6.9				8728347; 17060857	po	33.1	17.6	74.7	70.9					9630824
15.2				17396621										
				16239359										
		-80.2		NDA 021742	po	-31	71.1	254.3		39.3	-17.2	-53.3		NDA 021742
				8665999	po		30.8							8665999
	-11.9	-38.5		17050789										
35.6	-27.2	-25.8	5.5	20110053										
				6224683	po		20.1							6224683
					po	145.3	260.2	400.6	552.9	-54.7	-70.7	-79	-79.6	3471179
				11451213	po	62.1	82.1	178.7						11451213
179.4				14671680										
395.7	-55.9	-37.4	-79.9	8485026										
		19.3		15842560	o (oseltamivir)	137.2	258.5	929						10628898
	7.5	-9.8		NDA 203505	po			25.6				-11.3		NDA 203505
183.9	-4.3	9.7	-16.9	17575231	iv	22	32.9			-22	-27.6	-30.8		17699862
		34.9		19825324										
	-9.8			11558857										
		2	149	16534233										
41.7	-10.4	-35.8	-28.4	22282526										
	↔	-44.4		NDA 022465										
					sq		28.2	118.7			-17.8	-44.3		17555463
				NDA 202834										
				10368078	iv					-7.2				10368078
	-8.42	-68.9		NDA 022363	po		79.5	27	86.3		-44.3	-31.6	-46.3	NDA 022363, 22472908(severe)
30.5	-18.6	-35.9	-28.5	19886860	po	-11.4		1	-19.9	3.6	-3.6		235.6	15647411
				19744013	po (data of R-138727)		-8.3		-42.1					19744014
					po	-20	16	-39.2		25.3	-32.5	82.8		1613121
					po		77.4	228.9	495		-45.8	-70.4	-79.1	12638396
		-24.8		10958148	po			51.1				-25.6		10958148
	-63.5			10363734	po				-39.6				93.5	10471983
		-55.1		NDA 020815	po		71.2				-41.6			15801944
				19223645	po			-14.7						19223645
					po		-20.5	-5.1	20.8					3034037
					po (ramipril)		45.5	197	278					3034037
				15951470	po	75.4	70.8	99						16153399
	-42.4	-82		NDA 021641	po	45.1	-28.2			-24	26			NDA 021641
					po	96.6	111.9	181.2		-55.2	-56.1	-68.3		10806601
				NDA 203085	po	35.3	69.6							NDA 203085
2.7				10664920	po		15.2	33.3	32.3					10668848
107.1	3.4	-33.1	-52	NDA 022345	po	27.4	187.5	107.8	109.2	-27	-55.6	-53	-56.2	NDA 022345
21.3				10792198	po	80.9	111.6	228.5		-44	-54.6	-75.6		24071578
				NDA 202022										
		-34.9		8748391	po		180	106.8			-64.6	-52		8748391
	-18.3	-48.1	-64.2	19667283										
	-13.6	-57.6		23294275	po	49.4	65.8	78.7		-32.5	-40	-43.8		21039764
		-13.6		8010470	iv			264.9			-75	-40		20007792, 15816565(ESRD)

	-33.3	-41.7		17465639	po			-20.6						21781649
189.5			-60.4	17197844	iv		29.7	48.6			-5.2	-19.8		21307007
				12898007	po	10.1	14	-19.3	76	-6.5	-13	21.5		12638393, 19138247(ESRD)
				12610743	po	42	7	216	50					NDA 021366
		7.7		NDA 021829	transderma	-15.1	6.1	12.9	19.1	23.5	25.4	-12.5	1.3	NDA 021829
					po				1.9				8.8	16509761
					po				-20.4					NDA 021911
65				NDA 202192	po	16	40	30	70					NDA 202192
77				21348538	po	15.8	40.9	101.9	-20.9	-11.4	-28.1	-48	30.5	21348538
				15637531	po		494.3							15637531
		-45.8		11879256	po	-9.7	16.7	100.9		10.7	-14.2	-50.2		11879256
				NDA 22206	po		222.7							NDA 22206
209.9	-31.6	-36.3	-67.3	16291711; 18218785										
				19221403	po	61.1	126.4	277.3	350					17468348
		-42.8		17170513	po	49.9	31	112.6		-26.9	-18.8	-53.9		17251687
					po		120.8	40.6	57				-35.3	8031038, 10463518(mod)
					po	38.1	73.6	-2.7		-26.2	-42.6	1.6		8061846
					po (spirapri	109.2	184.2	273.9		-44.6	-64.6	-67.7		8061846
					po	18.8	93.6	218	239.4	-13.3	-46.9	-67.8	-98.2	10898689
					iv	96.1	542.2		1007.8	-50	-82		-90.3	3377461
	-9.3	-7.4		20049443	po			-5.3	-47.2			26.8	91.4	19779038
	-12.5			11402631										
	1.2	43.6		16869816	po	119	71.2		40.3	-54.4	-41.5		-28.7	16869816
					po		34.8		133.3			-6.9		11270803
					po		104.7	166.9			-44.3	-60.4		9696967
	-36.8	-72.6		NDA 22304	po	20.9	17.3	17.6		-12.1	-3.2	-2.9		NDA 22304
				NDA 203441	sq		52.2	72.4	159.1		-34	-42	-61.4	23187965
	4.5	32		NDA 201917	po			33.8						NDA 201917
		25.8		NDA 022110	iv	13	28.8	117.9	80.4	-11.7	-19	-54.9	-40.3	NDA 022110
59.6	-0.7	-17.8	-27.5	16641441	po	14				-9.6	-40.6	-69	-84.3	17875994
				12927950	po	28.6	18.6	89.5		-33.9	-19.5	-53.6		14973302
		-59.1		11185634										
	-3.8			NDA 022088										
35				17048975	po	41.3	162.1	749.5						17048975
					po						15.4			11881981
	13.4	41.2		NDA 202992	po			6.1				6.7		NDA 202992
				NDA 021894										
					iv			-14.7				16.7		12816178
				9118850	po	34.5	10.9	20.8	-17.2	-24.5	-1.8	-10.7	23.3	9578011
				NDA 022433	po			-20.3						21960668
104.2	4.7	-25.8	-54.7	20308689	iv			42.9	24.7			-24.8	-21.9	21953572
				17008695										
	-54.3			8803523										
		-22.5		12463726	iv			-33.8				-19.1		12463726
					iv	-11.1	5.9	22.7						NDA 125276
				NDA 203214	po	41	71	156						NDA 203214
		-20	-20	NDA 022275	po		79.4	89.2			-47.9	-41.8		24048380
		-13.9		8637048	iv					-32.5	-65	-15		8955651
		-27.5		7781262	po		0.4				-7.8			7781262
17.8				9832300										
		-39.8		346355										
				9333102										
-7	-4.2	6.3	7.6	20690783	po	14	39.1	41		-12	-29	-29.1		NDA 022405
					po	9.7	50.4	114.8		-1.3	-34.6	-49.7		21053991
		-35.9		2859815	iv								-41.8	2900610
	-13	-13.9	16.9	NDA 202499	po					-7.5	-4.7	-5.6		NDA 202429
					po				2.3				9.4	20481650
					po	30	100	253						NDA 020427
-28				23200625	inh			56.4						23200625
				NDA 022567	po	21.3	12.2			-24.6	-6.7			23417352
30	27.3	10.6	-13.1	17486328	po	38.7	74.4	115.6		-29.3	-40.1	-52.4		23782585
				20978276										
-21.1				22527342	po				-1.7				6	22315147
					po	67.8	44.9	-35.2		-40.4	-31	54.1		18544001
					iv		-36.4				52.7			18544001
				12846596	po			490				-79.3		12846595
					po		300.3	439.2			-68.2	-82.2		9597556

